GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

Completed

• Conditions: Diabetes Mellitus
• Interventions: Drug: Acarbose (Glucobay, BAYG5421)

• Registration Number: NCT00909051
• Lead Sponsor: Bayer

Brief Summary

Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-03-24
• Study First Submitted: 2009-05-26
• Study First Submitted QC: 2009-05-26
• Study First Posted: 2009-05-27
• Primary Completion: 2010-12-31
• Study Completion: 2010-12-31
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-05
• Last Update Posted: 2023-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15729

Inclusion Criteria

• Patients with untreated or pretreated diabetes mellitus or patients for which acarbose is indicated and without acarbose treatment within the last three months before study inclusion. The decision for treatment type and duration is taken by the investigator and is made before inclusion into the study.

Exclusion Criteria

• Exclusion criteria must be read in conjunction with the local product information.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group 1	Acarbose (Glucobay, BAYG5421)	-

Primary Outcome Measures

Name	Time	Method
Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI)	During observation period of three months